脐带间充质干细胞与脂肪源性血管基质组分治疗膝骨关节炎

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1357 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective〓To evaluate the clinical efficacy of human allogenic umbilical cord mesenchymal stem cells(UC-MSCs) and autologous fat-derived stromal vascular fraction(SVF) in the treatment of knee osteoarthritis.Methods〓Between January 2020 and June 2021，44 patients with osteoarthritis treated at the General Hospital of Northern Theater Command were randomly assigned to two groups：The UC-MSCs group (where UC-MSCs were injected into the articular cavity) and the SVF group (where SVF was injected into the joint cavity).The UC-MSCs group comprised 22 patients，including 8 males and 14 females，with an age range from 46 to 63 years and an average age of (55.6±5.8) years.Of these，13 cases involved the left knee and 9 cases the right knee.The SVF group also had 22 patients，including 10 males and 12 females，with an age range from 48 to 65 years and an average age of (55.2±7.3) years.Within this group，14 cases involved the left knee and 8 cases the right knee.Before injection and at 6 and 12 months post-injection，the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)，Lysholm score，visual analogue scale (VAS)，and imaging findings of the affected knee joint were used to comprehensively evaluate the efficacy of both treatment methods in managing knee osteoarthritis.Results〓 A total of 40 patients were followed up for a duration ranging from 12 to 21 months，averaging (14.9±5.2) months.However，four cases were lost to follow-up，with one from the UC-MSCs group and three from the SVF group.Preoperatively，there was no statistically significant difference in general information between the two groups (P＞0.05).Post-injection，the WOMAC score，Lysholm score，and VAS of patients in the UC-MSCs group were all superior to those in the SVF group (P＜0.05).During the follow-up period，no serious adverse reactions were observed in either group，but the incidence of adverse reactions in the UC-MSCs group was higher than that in the SVF group (P＜0.05).Conclusion〓Both formulations are effective in treating knee osteoarthritis.The efficacy of UC-MSCs is superior to SVF，but the incidence of adverse reactions (fever，swelling) after injection is higher than that of SVF.

Key words： mesenchymal stem cells stromal vascular fraction knee joint osteoarthritis cartilage regeneration

Corresponding Authors: Li Sitong

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Li Bao
	Cui Xianghong
	Li Han
	Liu Ming
	Li Haokun
	Liu Xinwei
	Li Sitong

Cite this article:

Li Bao,Cui Xianghong,Li Han, et al. Efficacy of Umbilical Cord Mesenchymal Stem Cells and Stromal Vascular Fraction in Treatment of Knee Osteoarthritis[J]. sygkzz, 2024, 30(6): 508-.

URL:

http://www.sygkzz.com/EN/ OR http://www.sygkzz.com/EN/Y2024/V30/I6/508

［1］Primorac D，Molnar V，Rod E，et al.Knee osteoarthritis：A review of pathogenesis and state-of-the-art non-operative therapeutic considerations［J］.Genes (Basel)，2020，11(8)：854.
［2］Mahmoudian A，Lohmander LS，Mobasheri A，et al.Early-stage symptomatic osteoarthritis of the knee-time for action［J］.Nat Rev Rheumatol，2021，17(10)：621-632.
［3］iestad BE，Juhl CB，Culvenor AG，et al.Knee extensor muscle weakness is a risk factor for the development of knee osteoarthritis：An updated systematic review and meta-analysis including 46 819 men and women［J］.Br J Sports Med，2022，56(6)：349-355.
［4］Zarringam D，Saris DBF，Bekkers JEJ.The value of SPECT/CT for knee osteoarthritis：A systematic review［J］.Cartilage，2021，12(4)：431-437.
［5］陈旭，付红英，彭娇等.膝骨关节炎病人生活质量与疼痛信念的相关性分析［J］.骨科，2023，14(4)：363-366.
［6］张文豪，热米拉·艾买提，张思平，等.干细胞再生医学治疗膝骨关节炎的展望［J］.实用骨科杂志，2023，29(11)：1046.
［7］Raeissadat SA，Ghazi Hosseini P，Bahrami MH，et al.The comparison effects of intra-articular injection of platelet rich plasma (PRP)，plasma rich in growth factor (PRGF)，hyaluronic acid (HA)，and ozone in knee osteoarthritis：A one year randomized clinical trial［J］.BMC Musculoskelet Disord，2021，22(1)：134.
［8］Huang R，Li W，Zhao Y，et al.Clinical efficacy and safety of stem cell therapy for knee osteoarthritis：A meta-analysis［J］.Medicine (Baltimore)，2020，99(11)：E19434.
［9］Amodeo G，Niada S，Moschetti G，et al.Secretome of human adipose-derived mesenchymal stem cell relieves pain and neuroinflammation independently of the route of administration in experimental osteoarthritis［J］.Brain Behav Immun，2021(94)：29-40.
［10］Matas J，Orrego M，Amenabar D，et al.Umbilical cord-derived mesenchymal stromal cells (MSCs) for knee osteoarthritis：Repeated MSC dosing is superior to a single MSC dose and to hyaluronic acid in a controlled randomized phase Ⅰ/Ⅱ trial［J］.Stem Cells Transl Med，2019，8(3)：215-224.
［11］Doyle EC，Wragg NM，Wilson SL.Intraarticular injection of bone marrow-derived mesenchymal stem cells enhances regeneration in knee osteoarthritis［J］.Knee Surg Sports Traumatol Arthrosc，2020，28(12)：3827-3842.
［12］Tsubosaka M，Matsumoto T，Sobajima S，et al.Comparison of clinical and imaging outcomes of different doses of adipose-derived stromal vascular fraction cell treatment for knee osteoarthritis［J］.Cell Transplant，2021(30)：9636897211067454.
［13］李涵，向杜磊，赵根，等.脂肪源性基质血管组分在膝关节软骨损伤治疗中的短期临床疗效［J］.骨科，2022，13(6)：507-510.
［14］Pavone V，Vescio A，Turchetta M，et al.Injection-based management of osteoarthritis of the knee：A systematic review of guidelines［J］.Front Pharmacol，2021(12)：661805.
［15］Millerand M，Berenbaum F，Jacques C.Danger signals and inflammaging in osteoarthritis［J］.Clin Exp Rheumatol，2019，120(5)：48-56.
［16］Geyer M，Schnfeld C.Novel insights into the pathogenesis of osteoarthritis［J］.Curr Rheumatol Rev，2018，14(2)：98-107.
［17］O'Neill TW，McCabe PS，McBeth J.Update on the epidemiology，risk factors and disease outcomes of osteoarthritis［J］.Best Pract Res Clin Rheumatol，2018，32(2)：312-326.
［18］曾国威，钟浩博，黎旭，等.膝关节渗液性滑膜炎与膝骨关节炎相关性的研究进展［J］.中华骨与关节外科杂志，2023，16(3)：282-288.
［19］Nguyen TH，Duong CM，Nguyen XH，et al.Mesenchymal stem cell-derived extracellular vesicles for osteoarthritis treatment：Extracellular matrix protection，chondrocyte and osteocyte physiology，pain and inflammation management［J］.Cells，2021，10(11)：2887.
［20］Fu X，Liu G，Halim A，et al.Mesenchymal stem cell migration and tissue repair［J］.Cells，2019，8(8)：784.
［21］Ezquerra S，Zuleta A，Arancibia R，et al.Functional properties of human-derived mesenchymal stem cell spheroids：A meta-analysis and systematic review［J］.Stem Cells Int，2021(2021)：8825332.
［22］肖昆林，张蕊，张维杰，等.间充质干细胞来源的外泌体对骨关节炎的治疗作用研究［J］.实用骨科杂志，2019，25(3)：232-236.
［23］Reddy KB.Stem cells：Current status and therapeutic implications［J］.Genes (Basel)，2020，11(11)：1372.
［24］Shamsuddin SA，Chan AML，Ng MH，et al.Stem cells as a potential therapy in managing various disorders of metabolic syndrome：A systematic review［J］.Am J Transl Res，2021，13(11)：12217-12227.
［25］Rodríguez-Fuentes DE，Fernández-Garza LE，Samia-Meza JA，et al.Mesenchymal stem cells current clinical applications：A systematic review［J］.Arch Med Res，2021，52(1)：93-101.
［26］Lim HC，Park YB，Ha CW，et al.Allogeneic umbilical cord blood-derived mesenchymal stem cell implantation versus microfracture for large，full-thickness cartilage defects in older patients：A multicenter randomized clinical trial and extended 5-year clinical follow-up［J］.Orthop J Sports Med，2021，9(1)：2325967120973052.
［27］Garza JR，Campbell RE，Tjoumakaris FP，et al.Clinical efficacy of intra-articular mesenchymal stromal cells for the treatment of knee osteoarthritis：A double-blinded prospective randomized controlled clinical trial［J］.Am J Sports Med，2020，48(3)：588-598.

[1]	. [J]. sygkzz, 2024, 30(6): 539-.